Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
Journal of Sleep Research
|
August 25, 2025
Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of Narcolepsy
Luis E Ortiz, Anne Marie Morse, Michael J Thorpy, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
July 20, 2021
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy
Russell Rosenberg, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep Medicine
|
July 25, 2021
The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis
Maurice M Ohayon, Michael J Thorpy, Ginger Carls, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
July 6, 2023
Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia
Anne Marie Morse, Yves Dauvilliers, Isabelle Arnulf, et al.
Sleep & Breathing = Schlaf & Atmung
|
April 13, 2011
Catathrenia under sodium oxybate in narcolepsy with cataplexy
Francesca Poli, Lara Ricotta, Stefano Vandi, et al.
CNS Drugs
|
June 27, 2020
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial
Yves Dauvilliers, Colin Shapiro, Geert Mayer, et al.
Sleep
|
August 13, 2021
Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
Richard K Bogan, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep
|
July 5, 2021
Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
Richard K Bogan, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep
|
November 13, 2020
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
Richard K Bogan, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep
|
August 6, 2021
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
Clete A Kushida, Colin M Shapiro, Thomas Roth, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
Journal of Sleep Research
|
August 25, 2025
Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of Narcolepsy
Luis E Ortiz, Anne Marie Morse, Michael J Thorpy, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
July 20, 2021
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy
Russell Rosenberg, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep Medicine
|
July 25, 2021
The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis
Maurice M Ohayon, Michael J Thorpy, Ginger Carls, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
July 6, 2023
Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia
Anne Marie Morse, Yves Dauvilliers, Isabelle Arnulf, et al.
Sleep & Breathing = Schlaf & Atmung
|
April 13, 2011
Catathrenia under sodium oxybate in narcolepsy with cataplexy
Francesca Poli, Lara Ricotta, Stefano Vandi, et al.
CNS Drugs
|
June 27, 2020
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial
Yves Dauvilliers, Colin Shapiro, Geert Mayer, et al.
Sleep
|
August 13, 2021
Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
Richard K Bogan, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep
|
July 5, 2021
Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
Richard K Bogan, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep
|
November 13, 2020
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
Richard K Bogan, Michael J Thorpy, Yves Dauvilliers, et al.
Sleep
|
August 6, 2021
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
Clete A Kushida, Colin M Shapiro, Thomas Roth, et al.
Page
of 8